Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Innovation Council · Finished

ACTIVE Articular Cartilage Treatment with Injectable hydrogel is Valuable and long-term Effective

Coordinator
Hy2care BV, Netherlands
Runs
1 October 2022 to 30 September 2024
Status
Finished
EU funding
€2.5m
Total cost
€3.7m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190135342

What the project is doing

In the project's own words, from its summary on CORDIS.

Hy2Care brings a regenerative Injectable Hydrogel, of joint- and cartilage-mimicking composition, that is used to treat damaged cartilage. The cartilage defects are easily filled with a syringe during a standard one time arthroscopy. The hydrogel fill the defect, prevents ingrowth of scar tissue and allows the body to heal itself by creating true Hyaline cartilage, ensuring an optimal regenerated tissue. The high-quality regeneration provides the basis for a long lasting repair, postponing or even preventing the onset of osteoarthritis.

The gel binds covalently to the surrounding cartilage ensuring integration of the new tissue. Revalidation is fast as the cartilage regrowth follows the degradation of the gel. The lasting repair not only prevents additional secondary treatments but also pain, disability and escalating follow-on costs. In submission of the last cut off of the EIC in october 2020 Hy2Care scored a 14.0 and recieved the seal of excellence.

Who is involved

OrganisationCityCountryRole
Hy2care BVGeleenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI